Publication
Randomized, multicentre phase II trial of the sequencing of radium-223 and docetaxel plus prednisone in symptomatic bone-only metastatic castration-resistant prostate cancer (mCRPC).
Vincenza Conteduca, Stefano Severi, Stefania Gori, Luca Galli, Michele Aieta, Gaetano Facchini, Cristina Masini, Donatello Gasparro, Lucia Fratino, Susanne Baier, Emanuela Scarpi, Sara Testoni, Valeria Sirna, Linda Valmorri, Bernadette Vertogen, Giovanni Paganelli, Ugo De Giorgi
Journal of Clinical Oncology, February 2018, American Society of Clinical Oncology (ASCO)
DOI: 10.1200/jco.2018.36.6_suppl.tps396